NASDAQ$CRVO
Diffusion Pharmaceuticals Inc · Q4 2019 earnings
Q4 2019 earnings · · Investor relations
Briefing
Announced the retirement of Chief Science Officer John L. Gainer, who will remain on the board of directors.
Diffusion Pharmaceuticals announced the retirement of Chief Science Officer John L. Gainer, who will continue to serve as an advisor and board member. The company has begun searching for a Chief Medical Officer to replace the Chief Science Officer position.
- Professor John L. Gainer, the company’s chief science officer, is retiring.
- Dr. Gainer will continue to serve as an advisor and member of the board of directors.
- The Company has begun a search for a Chief Medical Officer as a replacement for the former Chief Science Officer position.
- Diffusion’s on-ambulance PHAST-TSC trial for acute stroke has begun patient enrollment.
Headline financials
Revenue & EPS history
CervoMed · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2019
+0.4%
Avg return
Earnings day
+177.7%
Avg return
5 days after
-10.0%
Avg return
30 days after
31%
20 / 65 earnings
Positive
+39.3%
Q1 2020
Best reaction
-27.6%
Q3 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -8.5% | — | — | |
| Q4 2025 | +5.1% | -6.7% | -7.4% | |
| Q3 2025 | -0.3% | +11.0% | +25.3% | |
| Q2 2025 | +5.5% | +3.2% | +12.5% | |
| Q1 2025 | +0.0% | -4.1% | -17.3% | |
| Q4 2024 | +3.2% | +57.9% | +8.3% | |
| Q3 2024 | -7.6% | -11.3% | -84.1% | |
| Q2 2024 | +33.0% | +61.9% | +39.3% | |
| Q1 2024 | -1.4% | -20.1% | -23.0% | |
| Q4 2023 | -4.9% | -12.0% | +3.7% | |
| Q3 2023 | -2.6% | +0.2% | -10.6% | |
| Q2 2023 | -1.1% | +9.5% | +10.4% | |
| Q1 2023 | -5.4% | -1.7% | -11.3% | |
| Q4 2022 | -8.7% | -12.7% | -27.1% | |
| Q3 2022 | +21.4% | +22.0% | +28.6% | |
| Q2 2022 | -2.0% | -1.4% | -7.1% | |
| Q1 2022 | +18.6% | +25.5% | +25.5% | |
| Q4 2021 | -3.7% | +0.0% | -43.0% | |
| Q3 2021 | -6.7% | -4.4% | -15.6% | |
| Q2 2021 | -7.0% | -14.0% | -3.5% | |
| Q1 2021 | +0.0% | +6832.2% | +13.2% | |
| Q4 2020 | +4.9% | +4.9% | -99.1% | |
| Q3 2020 | -10.1% | -20.3% | -6.3% | |
| Q2 2020 | -0.9% | -1.8% | -22.7% | |
| Q1 2020 | +39.3% | +121.3% | +77.0% | |
| Q4 2019 | -8.8% | -17.6% | +17.6% | |
| Q3 2019 | -27.6% | -69.7% | -25.0% | |
| Q2 2019 | -0.9% | -3.7% | -10.6% | |
| Q1 2019 | -4.9% | -3.8% | -29.6% | |
| Q4 2018 | +3.8% | -4.3% | -33.6% | |
| Q3 2018 | +0.0% | -12.1% | -41.8% | |
| Q2 2018 | +2.8% | +13.9% | +11.1% | |
| Q4 2017 | -3.6% | -11.3% | -1.9% | |
| Q1 2018 | -3.6% | +1.8% | +1.8% | |
| Q3 2017 | -3.6% | -1.5% | +3.6% | |
| Q2 2017 | -7.7% | +0.0% | +12.5% | |
| Q4 2016 | -0.6% | +3.1% | -15.8% | |
| Q1 2017 | -0.6% | +3.1% | -15.8% | |
| Q3 2016 | -3.8% | -4.8% | -40.0% | |
| Q2 2016 | +0.0% | +0.0% | -90.0% | |
| Q1 2016 | +11.1% | — | — | |
| Q4 2015 | -6.4% | — | — | |
| Q3 2015 | -9.1% | — | — | |
| Q2 2015 | +1.2% | — | — | |
| Q1 2015 | -2.0% | — | — | |
| Q4 2014 | -7.1% | — | — | |
| Q3 2014 | -1.1% | — | — | |
| Q2 2014 | +4.5% | — | — | |
| Q1 2014 | -3.2% | — | — | |
| Q4 2013 | +0.0% | — | — | |
| Q3 2013 | +0.0% | — | — | |
| Q2 2013 | +0.0% | — | — | |
| Q1 2013 | +0.0% | — | — | |
| Q4 2012 | +18.8% | — | — | |
| Q3 2012 | +4.8% | — | — | |
| Q2 2012 | -2.6% | — | — | |
| Q1 2012 | +0.0% | — | — | |
| Q4 2011 | +8.0% | — | — | |
| Q3 2011 | -11.5% | — | — | |
| Q2 2011 | +7.1% | — | — | |
| Q1 2011 | +5.5% | — | — | |
| Q4 2010 | +1.6% | — | — | |
| Q3 2010 | +19.0% | — | — | |
| Q2 2010 | -12.0% | — | — | |
| Q1 2010 | +0.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro